Ravi K. Goyal

Employment

• Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
  2010 - 2013

Education

• University of Houston PhD
  2019 - 2022
• University of Houston College of Pharmacy

Projects & Funding

Projects & funding information is unavailable.

Publications (103)

• real-world healthcare resource utilisation (HCRU) and cost burden of coronavirus disease 2019 (covid-19) in adults at high risk of severe disease in the United States (US)1
  Congress of the European Society of Clinical Microbiology and Infectious Diseases 2026, Munich, Germany, 4/17/26 2026
  +Save
• Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
  Cancer Medicine 2025 DOI: 10.1002/cam4.70719
  +Save
• Association between dose reduction and duration of therapy in patients receiving ibrutinib or acalabrutinib for chronic lymphocytic leukemia: a medical chart review study.
  American Society of Hematology Annual Meeting & Exposition 2024, San Diego, United States, 12/7/24 2024
  +Save
• Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States
  Breast Cancer Research and Treatment 2024 DOI: 10.1007/s10549-024-07469-6
  +Save
• Exploring the Association Between Heart Rate Control and Rehospitalization: A Real-World Analysis of Patients Hospitalized with Heart Failure with Reduced Ejection Fraction
  Drugs - Real World Outcomes 2024 DOI: 10.1007/s40801-024-00436-z
  +Save
• Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe
  Future Oncology 2024 DOI: 10.1080/14796694.2024.2379228
  +Save
• Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study
  Future Oncology 2024 DOI: 10.2217/fon-2023-1064
  +Save
• Luspatercept utilization patterns in lower-risk myelodysplastic syndrome (LR-MDS): findings from a multinational medical record review study.
  European Hematology Association 2024 Hybrid Congress, Madrid, Spain, 6/13/24 2024
  +Save
• Social determinants of health and other predictors in initiation of treatment with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer
  Cancers 2024 DOI: 10.3390/cancers16122168
  +Save
• Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2-metastatic breast cancer
  Journal of Clinical Oncology 2024 DOI: 10.1200/JCO.2024.42.16_suppl.1111
  +Save